



OPEN ACCESS

EDITED BY

Akshay Kumar,
Medanta The Medicity Hospital, India

REVIEWED BY

Chengliang Yang,
University of British Columbia, Canada

*CORRESPONDENCE

Akshay J. Patel
✉ ajp.788@gmail.com

RECEIVED 22 February 2024

ACCEPTED 19 March 2024

PUBLISHED 08 April 2024

CITATION

Patel AJ and Bille A (2024) Lymph node
dissection in lung cancer surgery.
Front. Surg. 11:1389943.
doi: 10.3389/fsurg.2024.1389943

COPYRIGHT

© 2024 Patel and Bille. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).
The use, distribution or reproduction in other
forums is permitted, provided the original author
(s) and the copyright owner(s) are credited and
that the original publication in this journal is
cited, in accordance with accepted academic
practice. No use, distribution or reproduction is
permitted which does not comply with these
terms.

Lymph node dissection in lung cancer surgery

Akshay J. Patel^{1,2*} and Andrea Bille¹

¹Department of Thoracic Surgery, Guy's Hospital, Guy's and St. Thomas' Hospital NHS Trust, London, United Kingdom, ²Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

Lung cancer, a leading cause of cancer-related death, often requires surgical resection for early-stage cases, with recent data supporting less invasive resections for tumors smaller than 2 cm. Central to resection is lymph node assessment, an area of controversy worldwide, compounded by advances in minimally invasive techniques. The review aims to assess current standards for lymph node assessment, recent data from the surgical era, and the immunobiological basis of how lymph node metastases impact patient outcomes. The British Thoracic Society guidelines recommend systematic nodal dissection during lung cancer resection, without specifying node removal or sampling. Historical data on mediastinal lymph node dissection (MLND) survival benefits are inconclusive, although proponents argue for lower recurrence rates. Recent trials such as ACOSOG Z0030 found no survival difference between MLND and nodal sampling, reinforcing the need for robust staging. While lobe-specific dissection strategies have been proposed, they currently lack consensus. JCOG1413 aims to compare the clinical benefits of lobe-specific and systematic dissection. TNM-9 staging revisions emphasize the prognostic significance of single-station N2 involvement. Robotic surgery shows promise, with trials such as RAVAL, which reported comparable outcomes to video-assisted thoracic surgery (VATS) and improved lymph node sampling. Immunobiological insights suggest preserving key immunological sites during lymphadenectomy, especially for patients receiving adjuvant immunotherapy. In conclusion, the standard lymph node resection strategy remains unsettled. The debate between systematic and selective dissection continues, with implications for staging accuracy and patient outcomes. As minimally invasive techniques evolve, robotic surgery emerges as an effective and low-risk approach to delivering optimal lymph node assessment.

KEYWORDS

lymph nodal dissection, thoracic surgery, lung cancer, robotic surgery, minimally invasive therapy

Introduction

Lung cancer is the leading cause of cancer-related death worldwide (1). Early-stage lung cancer is amenable to surgical resection with good long-term disease control (2). Recent randomized data have shown that lung cancers smaller than 2 cm can be effectively treated with less extensive lung resection, such as segmentectomy or wedge resection, achieving good long-term outcomes (3, 4). Central to any lung resection is lymph node assessment, which is fundamentally important to the pathological staging of lung cancer. The extent of lymph node resection, whether it involves sampling or radical lymphadenectomy (dissection), remains an area of controversy, with different

surgical practices reported worldwide. The ongoing advances in minimally invasive surgical techniques, including robotic, video-assisted, or indeed uni-portals strategies have further contributed to the diversity of intraoperative approaches to lymph node assessment. The purpose of this review is to critically appraise the current standard of lymph node assessment, review recent data with respect to the current surgical era, and evaluate the immunobiological basis of lymph node metastases and how this translates to patient outcomes.

Current standard

The British Thoracic Society 2010 guidelines (5) advocate that the International Association of the Study of Lung Cancer (IASLC) nodal map (6) should be used in the assessment and staging of lymph node disease. Intraoperatively, one should perform systematic nodal dissection in all patients undergoing resection for lung cancer and remove or sample a minimum of six lymph node stations. The guidelines here do not provide any firm indication as to whether lymph nodes should be removed or sampled.

Sampling vs. dissection

Historical data addressing the survival benefit of mediastinal lymph node dissection (MLND) have largely yielded inconclusive results with no definite oncological benefit observed. Proponents of full lymph node clearance have stated that by removing occult N2 disease, there is a lower chance of recurrence, hence leading to improved disease-free survival (7). However, it is worth noting that the commonest recurrence pattern in N2 disease is in distant anatomical sites (8). The most contemporary data come from the Canadian study, ACOSOG Z0030 trial, which randomized T1–T2 non-small cell lung cancer (NSCLC) patients to either no further lymph node sampling or full MLND after comprehensive mediastinal staging with negative lymph nodes (2R, 4R, 7, and 10R for right-sided lesions and 5, 6, 7, 10L for left-sided lesions) (7). This trial showed no difference in median survival between no sampling and MLND (8.1 vs. 8.5 years, $p = 0.25$) and no difference in locoregional and distant recurrence. Five-year disease-free survival rates were also not different between the groups; 69% vs. 68%, $p = 0.92$ respectively. However, occult N2 disease was found in 21 patients in the MLND group. This data was not translatable to higher-stage disease or patients with known pre-op N1/N2 disease. Given that current preoperative staging cannot reliably rule out N2 disease, MLND is still recommended given that there is no increased risk of morbidity or mortality. The current era of neoadjuvant immunotherapy, which is rapidly evolving and indeed improving overall and event-free survival, makes the case for robust staging to properly stratify patients into the correct treatment arms. Furthermore, data from this setting have shown significantly improved outcomes in those patients who incur a pathologic complete response (pCR) (9–12), which is all the more reason to

perform MLND to ensure firm ascription of the pCR or major pathologic response (MPR) states. We know from meta-analytical data from 209 patients across six studies that neoadjuvant immunotherapy offers comparable nodal downstaging (ypN0) to that of ypT(MPR) (OR 1.31 95% CI: 0.84–2.05) and results in satisfactory responses in metastatic lymph nodes (13).

Further work is needed to investigate the pathology of lung cancers resected in the neoadjuvant setting, and criteria have been described by Travis et al. (14); uniformity of surgical resection and completeness of tissue removal are likely to be core tenets of enhancing knowledge and thus care.

Lobe-specific vs. systematic dissection

Lobe-specific dissection has been described by numerous centers worldwide. This technique focuses on the characteristic mediastinal nodal metastasis patterns that occur depending on the primary tumor location and hence advocates only the dissection of specific draining nodal stations. Clinical trial data from Shanghai (15) has shown that in the setting of cT1N0 NSCLC, there is a specific mediastinal lymph nodal metastasis pattern and thus provides credence to the rationale of a selective lymph node dissection strategy.

Studies, predominantly from the East Asian subcontinent, investigating lobe-specific vs. systematic dissection have reported no major differences in strategy with respect to overall survival, occult N2 rate, and postoperative complication (16). However, data from Okada et al. (17) demonstrated a much higher complication rate postoperatively with systematic nodal dissection (17.3% vs. 10.1%, $p = 0.005$), with the most common problem being arrhythmia. Meta-analytical data (18) from 13 studies and 11,522 patients indicated that lobe-specific nodal dissection had favorable overall survival [hazard ratio (HR)] 0.80, 95% CI: 0.73–0.87] but no difference in recurrence-free survival (HR 0.96, 95% CI: 0.84–1.09) compared to systematic nodal dissection. This study concurred that there was a lower rate of postoperative complications in patients undergoing lobe-specific nodal dissection, e.g., chylothorax [risk ratio (RR) 0.54, 95% CI: 0.35–0.85] and arrhythmia (RR 0.74, 95% CI: 0.57–0.97), than those in patients undergoing systematic nodal dissection.

A large retrospective series from Sloan Kettering (19) showed that in 1,667 patients who all underwent systematic nodal dissection, an overall occult pN2 rate of 9% ($n = 146$) was observed. Moreover, of these patients, 16% ($n = 22$) had mediastinal lymph node metastases beyond the lobe-specific lymphatic drainage; hence, the authors advocated for systematic nodal dissection in all stages of lung cancer (19). It is worth noting that half of these patients ($n = 11$) had multi-station N2 and hence would have still been staged as pN2 through lobe-specific dissection. Balancing the risk of postoperative morbidity and the risk of missing occult N2 disease remains an area of contention more so in the setting of cT1a/b cancers.

The Japanese Clinical Oncology Group (JCOG) has commenced recruitment for a randomized trial (JCOG1413) to

confirm the clinical benefit of lobe-specific nodal dissection for stage I-II NSCLC. The primary endpoint is overall survival, and the trial has a non-inferiority design compared to systematic dissection in the setting of lobectomy. The secondary endpoints include relapse-free survival, % local recurrence, % regional lymph node recurrence, and adverse events with a plan to recruit 1,700 patients (20).

Implication of the TNM-9 staging system

Data have been recently accrued for the revision of the nodal status staging descriptors for the new TNM-9 staging system (21). For clinical (c) and pathological (p) nodal status, data from 45,032 and 35,009 patients, respectively, were made available. N0 to N3 status reflects the pathologically distinct groups, and as demonstrated by TNM-8, each progressive strata has significantly worse survival. Further interrogation of the divisions has shown that single-station N2 involvement (N2a) exhibits a better prognosis than multi-station N2 (N2b) in both clinical and pathological classifications. The difference between N2a and N2b was prognostically significant. From the clinical and pathological classifications, HR for death for N2b and N2a was 1.27 (95% CI: 1.13–1.43; $p < 0.0001$) and 1.46 (95% CI: 1.32–1.62; $p < 0.0001$), respectively. This implementation shows that detection of occult N2 even if single station will be of significant prognostic value and the chance of detection may well be higher through systematic dissection. Data from JCOG1413 will help answer this question, particularly in light of the upcoming TNM revisions.

Minimally invasive surgical advances and implications on lymph node dissection

Robotic surgery has evolved rapidly worldwide in the last 5 years in thoracic surgery. Clear advantages have been reported on a center-specific level, namely, enhanced visualization, the ability to dissect into the mediastinum, segmental resection, and lymph node dissection (22). From a more objective perspective, three randomized trials have directly compared robotic [robotic-assisted thoracic surgery (RATS)] vs. conventional video-assisted [video-assisted thoracic surgery (VATS)] approaches in lung resection surgery, namely, RAVAL, ROMAN, and RVLob (23–27).

The RAVAL trial (24) primarily sought to assess the health-related quality of life measures for patients following RATS lung cancer resection. Patients were randomized into a 1:1 ratio to either RATS or VATS-lobectomy. From 164 patients (RATS: $n = 81$; VATS: $n = 83$), the mean 12-week health utility score was 0.85 (0.10) for RATS and 0.80 (0.19) for VATS ($p = 0.02$). Significantly, more lymph nodes were sampled [10 (8–13) vs. 8 (5–10); $p = 0.003$] in the RATS arm. The incremental cost/quality-adjusted life year of RATS was \$14,925.62 (95% CI: \$6,843.69, \$23,007.56) at 12 months. The authors concluded that RATS is cost-effective and associated with comparable short-term

patient-reported health utility scores when compared with VATS-lobectomy. This could well mature further as we learn more about the implications of different lymph node dissection strategies and the advantage that the robotic approach has in this regard.

The ROMAN study (27) conducted a similarly designed trial in the setting of lung cancer; however, the primary outcome measure was the incidence of adverse events including complications and conversion to thoracotomy. The secondary objectives included the extent of lymph node dissection. The trial closed early due to the lack of favor for the robotic arm in terms of the primary outcome measure. Despite finding no difference between the two arms in perioperative complications, conversions, duration of surgery, or duration of postoperative stay, a significantly greater degree of lymph node assessment by the robotic technique was observed in regards to the median number of sampled nodal stations [6, interquartile range (IQR) 4–6 vs. 4, IQR 3–5; $p = 0.0002$], hilar LNs (7, IQR 5–10 vs. 4, IQR 2–7; $p = 0.0003$), and mediastinal LNs (7, IQR 5–10 vs. 5, IQR 3–7; $p = 0.0001$) (27). Similar findings were shown by the RVLob trial (25), in which the RATS group had a significantly higher number of lymph nodes harvested [11 (IQR, 8–15) vs. 10 (IQR, 8–13), $p = 0.02$], a higher number of N1 nodes [6 (IQR, 4–8) vs. 5 (IQR, 3–7), $p = 0.005$], and more nodal stations examined [6 (IQR, 5–7) vs. 5 (IQR, 4–6), $p < 0.001$]. Health-related quality of life and pain scores between the two groups were comparable up to 48 weeks postoperatively (24).

Robotic surgery albeit in its infancy has thus far shown utility in lymph node dissection and may well demonstrate utility and lower incidence of postoperative complications with respect to VATS when specifically assessing systematic lymph node dissection. This remains to be further elucidated. Given the recent data highlighting the utility of segmental resection, the robotic approach may further provide intraoperative superiority for intersegmental lymph node dissection and segment-specific dissection for very early-stage cancers. Long-term data maturation is still required when doing a head-to-head comparison between the two techniques, particularly in regard to long-term cost implications and survival implications, which have thus far not been demonstrated in minimally invasive surgery over open surgery (28, 29) and of course long-term morbidity and quality of life metrics.

Immunobiological implications of lymph node resection

Murine tumor model data have shown that tumor-draining lymph nodes (TDLNs) are enriched for tumor-specific PD-1+ T cells, which are closely associated with PD-L1+ conventional dendritic cells (cDCs) (30). TDLN-targeted PD-L1 blockade induces enhanced antitumor T-cell immunity by seeding the tumor site with progenitor-exhausted T cells, resulting in improved tumor control. This data highlights the TDLN as a key site of immune regulation and control over the tumor microenvironment; thus, expanded dissection of the said nodes

may lead to immune impairment due to less antigen exposure and immune priming. Further murine data were generated (31) from a metastatic lung cancer model where the primary subcutaneous tumors were resected with associated draining lymph nodes (dLN) remaining intact, completely resected, or partially resected. The median survival after surgery was significantly shorter with complete dLN resection at the time of surgery (49 days) compared to when lymph nodes remained intact (>88 days; $p < 0.05$). Survival was partially restored with incomplete lymph node resection and was CD8+ T-cell dependent. Similar observations were generated from Fransen's study (32) where surgical resection of TDLNs, but not contralateral lymph nodes, abolished therapy-induced tumor regressions and was associated with decreased immune infiltrate in the tumor microenvironment.

Application of these principles to the human setting was explored by Deng et al. (33) who retrospectively analyzed 144 patients with NSCLC who had recurred post-resection and stratified their outcomes based on TDLN count. Multivariate testing showed that a TDLN count of <16 (i.e., fewer nodes resected at the time of surgery) was associated with improved progression-free survival (PFS) in all cohorts [HR 0.26 (0.07–0.89), $p = 0.03$]. The prognostic benefit of a dLN count of ≤ 16 was more significant in immunotherapy alone, with no adjuvant treatment, pN1, female, and squamous carcinoma subgroups. A higher level of CD8+ central memory T cell (Tcm) within TDLNs was associated with improved PFS (HR: 0.235, 95% CI: 0.065–0.845, $p = 0.027$). Murine data from the syngeneic E0771 triple-negative breast cancer model showed that CD8+ T-cell priming occurs extratumorally in the dLN and the said antigenic priming is key to the survival of robust antitumor effector T-cell responses particularly in the context of checkpoint blockade (34). Progenitor-exhausted CD8+ T cells were abundant in uninvolved lymph nodes and mediate responses post-checkpoint blockade, but these responses were disrupted in metastatic lymph nodes (35).

Therefore, for patients planned for adjuvant immunotherapy, a precise rather than expanded lymphadenectomy strategy to preserve these key immunological sites upon which CD8+ priming is dependent may be important and worth consideration.

Conclusions

There is no well-preserved standard on reproducible lymph node resection strategy to date. Systematic (MLND) vs. sampling was an early question that was only partially answered by ACOSOG Z0030. MLND was the preferred approach, but in early-stage (cT1) disease, there was a mixture of practice between sampling and MLND. Most studies do not include stage I disease only hence the controversy. Given the increased use of

neoadjuvant immunotherapy, pathological interpretation is becoming more complex and necessary to determine factors such as MPR, pCR, and immunohistochemical features. Thus, it makes sense to perform MLND for robust pathological analysis and staging. The second question that remains largely unanswered is whether a selective strategy (lobe-specific) or a complete lymphadenectomy is performed. This is currently balanced on factors such as implications of TNM-9 staging and prognostication, lymph node immunobiology in the context of checkpoint blockade, and the incidence of postoperative complications. The implications of JCOG1413 are far-reaching and will hopefully serve to address these issues with impunity. In the era of minimally invasive surgery, whatever lymph node strategies are deemed most effective, the robotic approach will be able to effectively deliver with a low burden of morbidity and mortality.

Author contributions

AP: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. AB: Data curation, Supervision, Validation, Visualization, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. (2010) 127(12):2893–917. doi: 10.1002/ijc.25516
2. Ginsberg RJ, Rubinstein LV, Lung cancer study group. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. *Ann Thorac Surg*. (1995) 60(3):615–22. doi: 10.1016/0003-4975(95)00537-U

3. Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer. *N Engl J Med.* (2023) 388(6):489–98. doi: 10.1056/NEJMoa2212083
4. Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG46071): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. *Lancet.* (2022) 399(10335):1607–17. doi: 10.1016/S0140-6736(21)02333-3
5. Lim E, Baldwin D, Beckles M, Duffy J, Entwisle J, Favier-Finn C, et al. Guidelines on the radical management of patients with lung cancer. *Thorax.* (2010) 65(Suppl 3):iii1–27.
6. El-Sherief AH, Lau CT, Wu CC, Drake RL, Abbott GF, Rice TW. International Association for the Study of Lung Cancer (IASLC) lymph node map: radiologic review with CT illustration. *RadioGraphics.* (2014) 34(6):1680–91. doi: 10.1148/rg.346130097
7. Darling GE, Allen MS, Decker PA, Ballman K, Malhaner RA, Richard I, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the ACOSOG Z0030 trial. *J Thorac Cardiovasc Surg.* (2011) 141(3):662–70. doi: 10.1016/j.jtcvs.2010.11.008
8. Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, et al. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. *Cancer.* (2009) 115(18):4156–66. doi: 10.1002/cncr.24492
9. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. *N Engl J Med.* (2022) 386(21):1973–85. doi: 10.1056/NEJMoa2202170
10. Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galfy G, Hochmair M, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. *N Engl J Med.* (2023) 389(18):1672–84. doi: 10.1056/NEJMoa2304875
11. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. *N Engl J Med.* (2023) 389(6):491–503. doi: 10.1056/NEJMoa2302983
12. Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, et al. Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. *N Engl J Med.* (2023) 389(6):504–13. doi: 10.1056/NEJMoa2215530
13. Zhai WY, Zhao ZR, Chen S, Yu H, Lin YB, Wang YZ, et al. Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis. *J Immunother Cancer.* (2022) 10(9):e005160.
14. Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, et al. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens following neoadjuvant therapy. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer.* (2020) 15(5):709–40.
15. Zhang Y, Deng C, Zheng Q, Qian B, Ma J, Zhang C, et al. Selective mediastinal lymph node dissection strategy for clinical T1N0 invasive lung cancer: a prospective, multicenter, clinical trial. *J Thorac Oncol.* (2023) 18(7):931–9. doi: 10.1016/j.jtho.2023.02.010
16. Adachi H, Maehara T, Nakayama H, Masuda M. Mediastinal lymph node dissection in surgical treatment for early stage non-small-cell lung cancer: lobe-specific or systematic? *J Thorac Dis.* (2017) 9(9):2728–31. doi: 10.21037/jtd.2017.07.77
17. Okada M, Sakamoto T, Yuki T, Mimura T, Miyoshi K, Tsubota N. Selective mediastinal lymphadenectomy for clinico-surgical stage I non-small cell lung cancer. *Ann Thorac Surg.* (2006) 81(3):1028–32. doi: 10.1016/j.athoracsur.2005.09.078
18. Woo W, Shin JJ, Kipkorir V, Yang YH, Lee S, Lee CY. Clinical benefits of lobe-specific lymph node dissection in surgery for NSCLC: a systematic review and meta-analysis. *JTO Clin Res Rep.* (2023) 4(5). Available online at: [https://www.jtocrr.org/article/S2666-3643\(23\)00055-3/fulltext](https://www.jtocrr.org/article/S2666-3643(23)00055-3/fulltext)
19. Bille A, Woo KM, Ahmad U, Rizk NP, Jones DR. Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients. *Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg.* (2017) 51(4):674–9. doi: 10.1093/ejcts/ezw400
20. Hishida T, Saji H, Watanabe SI, Asamura H, Aokage K, Mizutani T, et al. A randomized phase III trial of lobe-specific vs. systematic nodal dissection for clinical stage I-II non-small cell lung cancer (JCOG1413). *Jpn J Clin Oncol.* (2018) 48(2):190–4. doi: 10.1093/jjco/hyx170
21. Huang J, Osarogiagbon RU, Giroux DJ, Nishimura KK, Bille A, Cardillo G, et al. The International Association for the Study of Lung Cancer staging project for lung cancer: proposals for the revision of the N descriptors in the forthcoming ninth edition of the TNM classification for lung cancer. *J Thorac Oncol.* (2023). (cited 2024 Jan 29). Available online at: [https://www.jto.org/article/S1556-0864\(23\)02310-9/fulltext](https://www.jto.org/article/S1556-0864(23)02310-9/fulltext)
22. Gossot D, Mariolo AV, Lefevre M, Boddaert G, Brian E, Grigoriou M, et al. Strategies of lymph node dissection during sublobar resection for early-stage lung cancer. *Front Surg.* (2021) 8. doi: 10.3389/fsurg.2021.725005
23. Patel YS, Hanna WC, Fahim C, Shargall Y, Waddell TK, Yasufuku K, et al. RAVAL trial: protocol of an international, multi-centered, blinded, randomized controlled trial comparing robotic-assisted versus video-assisted lobectomy for early-stage lung cancer. *PLoS One.* (2022) 17(2):e0261767.
24. Patel YS, Baste JM, Shargall Y, Waddell TK, Yasufuku K, Machuca TN, et al. Robotic lobectomy is cost-effective and provides comparable health utility scores to video-assisted lobectomy: early results of the RAVAL trial. *Ann Surg.* (2023) 278(6):841–9. doi: 10.1097/SLA.0000000000006073
25. Jin R, Zheng Y, Yuan Y, Han D, Cao Y, Zhang Y, et al. Robotic-assisted versus video-assisted thoracoscopic lobectomy: short-term results of a randomized clinical trial (RVlob trial). *Ann Surg.* (2022) 275(2):295–302. doi: 10.1097/SLA.0000000000004922
26. Jin R, Zhang Z, Zheng Y, Niu Z, Sun S, Cao Y, et al. Health-related quality of life following robotic-assisted or video-assisted lobectomy in patients with non-small cell lung cancer: results from the RVlob randomized clinical trial. *Chest.* (2023) 163(6):1576–88. doi: 10.1016/j.chest.2022.12.037
27. Veronesi G, Abbas AES, Muriana P, Lembo R, Bottoni E, Perroni G, et al. Perioperative outcome of robotic approach versus manual videothoracoscopic major resection in patients affected by early lung cancer: results of a randomized multicentric study (ROMAN study). *Front Oncol.* (2021) 11:726408. doi: 10.3389/fonc.2021.726408
28. Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. *Lancet Oncol.* (2016) 17(6):836–44.
29. Lim E, Batchelor TJP, Dunning J, Shackcloth M, Anikin V, Naidu B, et al. Video-assisted thoracoscopic or open lobectomy in early-stage lung cancer. *NEJM Evid.* (2022) 1(3):EVIDo2100016.
30. Dammeyer F, van Guljik M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, et al. The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. *Cancer Cell.* (2020) 38(5):685–700.8. doi: 10.1016/j.ccell.2020.09.001
31. Fear VS, Forbes CA, Neeve SA, Fisher SA, Chee J, Waithman J, et al. Tumour draining lymph node-generated CD8T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. *Cancer Immunol Immunother CII.* (2021) 70(11):3249–58. doi: 10.1007/s00262-021-02934-3
32. Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M, et al. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. *JCI Insight.* (2018) 3(23):e124507. 124507. doi: 10.1172/jci.insight.124507
33. Deng H, Zhou J, Chen H, Cai X, Zhong R, Li F, et al. Impact of lymphadenectomy extent on immunotherapy efficacy in post-resectional recurrent non-small cell lung cancer: a multi-institutional retrospective cohort study. *Int J Surg Lond Engl.* (2023).
34. O'Melia MJ, Manspeaker MP, Thomas SN. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC. *Cancer Immunol Immunother CII.* (2021) 70(8):2179–95. doi: 10.1007/s00262-020-02792-5
35. Rahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, et al. Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. *Cell.* (2023) 186(6):1127–1143.18. doi: 10.1016/j.cell.2023.02.021